Nothing new in the Shire report, but Pfizer's Q1 will be out tomorrow. If results of the ponezumab CAA analysis are ready and interesting enough they could be included.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.